Product Description
Mechanisms of Action: 5-HT2A Antagonist,GPIIb/IIIa Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: India | Korea
Approved Indications: None
Known Adverse Events: None
Company: Daewoong
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Kidney Diseases|Angina Pectoris, Variant|Coronary Artery Disease|Myocardial Ischemia|Diabetic Nephropathy|Peripheral Arterial Disease|Peripheral Vascular Diseases|Thrombophilia|Intermittent Claudication|Arterial Occlusive Diseases|Kidney Failure, Chronic
Phase 3: Ischemic Stroke|Kidney Failure, Chronic|Coronary Artery Disease|Peripheral Vascular Diseases|Peripheral Arterial Disease|Myocardial Ischemia
Phase 1: Healthy Volunteers|Chronic Pain|Peripheral Arterial Disease|Hypertension|Malnutrition
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
SEUMC 2023-10-009 | N/A |
Not yet recruiting |
Atherosclerosis|Intermittent Claudication|Stroke |
2028-06-30 |
|
YMC047 | P4 |
Recruiting |
Coronary Artery Disease|Myocardial Ischemia|Peripheral Arterial Disease|Peripheral Vascular Diseases |
2024-02-28 |
|
YMC044 | P4 |
Completed |
Arterial Occlusive Diseases|Intermittent Claudication |
2023-03-09 |
|
DWAP_P401 | N/A |
Completed |
Arterial Occlusive Diseases |
2022-01-20 |